N⁵-methyl-DL-glutamine | 4703-52-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N⁵-methyl-DL-glutamine
• 英文别名: N⁵-Methyl-DL-glutamin；N^δ-Methyl-glutamin；γ-Glutamyl-methylamid；2-azaniumyl-5-(methylamino)-5-oxopentanoate
• CAS: 4703-52-0
• 化学式: C₆H₁₂N₂O₃
• 分子量: 160.173
• InChiKey: ONXPDKGXOOORHB-UHFFFAOYSA-N

物化性质

• 沸点：
  431.0±40.0 °C(Predicted)
• 密度：
  1.211±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -3.9
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  92.4
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1-甲基-6-氧代-1,4,5,6-四氢哒嗪-3-甲酸 在 palladium on activated charcoal 、 水 作用下， 生成 N⁵-methyl-DL-glutamine
  参考文献：
  名称：

  Process for synthesizing glutamine

  摘要：

  公开号：

  US02873294A1

文献信息

• Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase
  申请人：Nair Vasu

  公开号：US20060172973A1

  公开（公告）日：2006-08-03

  A new class of diketo acids constructed on nucleobase scaffolds, designed as inhibitors of HIV replication through inhibition of HIV integrase, is described. These compounds are useful in the prevention or treatment of infection by HIV and in the treatment of AIDS and ARC, either as the compounds, or as pharmaceutically acceptable salts, with pharmaceutically acceptable carriers, used alone or in combination with antivirals, immunomodulators, antibiotics, vaccines, and other therapeutic agents. Methods of treating AIDS and ARC and methods of treating or preventing infection by HIV are also described.

  一种新型的二酮酸类化合物，构建在核碱基支架上，设计为通过抑制HIV整合酶来抑制HIV复制，这些化合物可用于预防或治疗HIV感染，治疗艾滋病和ARC，可以作为化合物或药用盐的形式，与药用载体一起使用，单独或与抗病毒药物、免疫调节剂、抗生素、疫苗和其他治疗药物联合使用。还描述了治疗艾滋病和ARC的方法，以及治疗或预防HIV感染的方法。
• Diketo acids on nucleobase scaffolds as inhibitors of Flaviviridae
  申请人：Nair Vasu

  公开号：US20060223834A1

  公开（公告）日：2006-10-05

  A new class of diketo acids constructed on nucleobase scaffolds, designed as inhibitors of HCV replication through inhibition of HCV NS5B RNA polymerase, is described. These compounds are useful in the prevention or treatment of infection by HCV and in the treatment of other Flaviviridae infections, either as the compounds, or as pharmaceutically acceptable salts, with pharmaceutically acceptable carriers, used alone or in combination with antivirals, immunomodulators, antibiotics, vaccines, and other therapeutic agents. Methods of treating HCV and methods of treating or preventing infection by HCV are also described.

  一种新型的二酮酸类化合物，构建在核碱基支架上，设计为通过抑制HCV NS5B RNA聚合酶来抑制HCV复制，这些化合物可用于预防或治疗HCV感染，以及治疗其他黄病毒科感染，可以作为化合物或药用盐的形式，与药用载体一起使用，单独或与抗病毒药物、免疫调节剂、抗生素、疫苗和其他治疗药物联合使用。还描述了治疗HCV的方法以及治疗或预防HCV感染的方法。
• [EN] 2-OXO-THIAZOLE DERIVATIVES AS A2A INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS<br/>[FR] DÉRIVÉS DE 2-OXO-THIAZOLE EN TANT QU'INHIBITEURS DE A2A ET COMPOSÉS DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE CANCERS
  申请人：ITEOS THERAPEUTICS

  公开号：WO2018178338A1

  公开（公告）日：2018-10-04

  The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof. The invention further relates to the use of the compounds of Formula (I) as A2A inhibitors. The invention also relates to the use of the compounds of Formula (I) for the treatment and/or prevention of cancer. The invention also relates to a process for manufacturing compounds of Formula (I).

  本发明涉及式（I）的化合物或其药用可接受的盐或溶剂化合物。该发明进一步涉及将式（I）的化合物用作A2A抑制剂。该发明还涉及将式（I）的化合物用于治疗和/或预防癌症。该发明还涉及一种制造式（I）化合物的方法。
• ALKOXYCARBONATE ESTER PRODRUGS FOR USE AS ANTIMALARIAL AGENTS
  申请人：OREGON HEALTH & SCIENCE UNIVERSITY

  公开号：US20200369616A1

  公开（公告）日：2020-11-26

  Provided are compounds of Formula (I): wherein: X is selected from the group of F and Cl; Y is selected from the group of —CH 2 —, —CH 2 —CH 2 —, and —CH(CH 3 )—; R 1 is selected from cycloalkyl, heterocyclyl, aromatic, heteroaromatic, and linear and branched alkyl, alkenyl, and alkynyl chains.

  提供的是Formula (I)的化合物： 其中：X选自F和Cl；Y选自—CH2—、—CH2—CH2—和—CH(CH3)—；R1选自环烷基、杂环烷基、芳香族、杂芳香族以及直链和支链烷基、烯基和炔基链。
• PYRIDAZINONE DERIVATIVES
  申请人：Stieber Frank

  公开号：US20110257181A1

  公开（公告）日：2011-10-20

  Compounds of the formula (I), in which Y, R 1 , R 2 , R 3 and R 3′ have the meanings indicated in claim 1 , are inhibitors of tyrosine kinases, in particular of Met kinase, and can be employed, inter alia, for the treatment of tumours.

  公式(I)中的化合物，其中Y、R1、R2、R3和R3'具有权利要求1中指出的含义，是酪氨酸激酶的抑制剂，特别是Met激酶的抑制剂，并且可以用于治疗肿瘤等。